Essex Bio-Technology Joins X-ZELL Seed+ Investment Round Singapore/Hong Kong, April 2020 – Rare cell detection specialist X-ZELL has entered into an investment agreement with Essex Bio-Investment, a wholly owned subsidiary of Essex Bio-Technology Ltd (“EssexBio”)....
X-ZELL featured in German life science magazine Laborjournal Freiburg, April 2020 – X-ZELL has been featured in the April edition of Laborjournal, one of Germany’s leading life science publications. The extensive company profile, penned by science journalist Dr...
INTERVIEW Krebs im BLUT Due to the overwhelming response to X-ZELL’s recent Live Sessions tour around Germany, we sat down with X-ZELL Founder & CEO, Dr Sebastian Bhakdi, to interview him in his native language. Singapur, Februar 2020 – Der deutsche Arzt Dr....
X-ZELL Cryoimmunostaining™ technology live in Europe Brussels, February 2020 – Following the official European launch of X-ZELL Cryoimmunostaining™ in November 2019, the Singapore start-up will be holding a series of Live Sessions in 2020 in order to introduce the new...
X-ZELL selected as Finalist for 2020 Hello Tomorrow Global Challenge Singapore, January 2020 – Singapore med tech start-up, X-ZELL, has been nominated as a Global Finalist for the 2020 Hello Tomorrow Challenge. Considered one of the world’s leading deep tech start-up...
X-ZELL named Deep Tech Pioneer by Hello Tomorrow Singapore, November 2019 – On the back of qualifying for the regional final of the prestigious Hello Tomorrow Challenge, X-ZELL has now been selected as one of Hello Tomorrow’s Deep Tech Pioneers. According to the...
